We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$110M
AUM Growth
-$16.5M
Cap. Flow
-$14M
Cap. Flow %
-12.81%
Top 10 Hldgs %
87.26%
Holding
31
New
11
Increased
5
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$2.81M
2
ANIK icon
Anika Therapeutics
ANIK
+$2.71M
3
OPTN
OptiNose
OPTN
+$2.62M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.59M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$2.26M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$13.1M
2
EOLS icon
Evolus
EOLS
+$12.5M
3
NKTR icon
Nektar Therapeutics
NKTR
+$3.25M
4
CALC icon
CalciMedica
CALC
+$2.17M
5
ALIM
Alimera Sciences
ALIM
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALC icon
26
CalciMedica
CALC
$11.1M
– –
-522,602
Closed -$2.17M
IOBT
27
DELISTED
IO Biotech
IOBT
– –
-156,167
Closed -$270K
NKTR icon
28
Nektar Therapeutics
NKTR
$2.41B
– –
-232,027
Closed -$3.25M
RZLT icon
29
Rezolute
RZLT
$476M
– –
-121,479
Closed -$310K
SCYX icon
30
SCYNEXIS
SCYX
$35.5M
– –
-11,955
Closed -$141K
XERS icon
31
Xeris Biopharma Holdings
XERS
$1.42B
– –
-598,086
Closed -$1.32M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Stonepine Capital Management held 31 positions worth $110M, down 13% from $126M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Stonepine Capital Management withdrew a net $14M in Q2 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Nektar Therapeutics, an estimated $3.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in OptiNose worth $2.44M.

  • Stonepine Capital Management's largest Q2 2024 buy was OptiNose: 156,667 shares worth $2.44M.
  • Stonepine Capital Management added most to Revance Therapeutics, Inc. in Q2 2024, an estimated $2.81M increase.
  • Stonepine Capital Management's biggest Q2 2024 reduction was ADMA Biologics, cutting an estimated $13.1M.
  • Stonepine Capital Management fully exited Nektar Therapeutics in Q2 2024, selling an estimated $3.25M.
  • Stonepine Capital Management's ten largest holdings make up 87% of its $110M portfolio in Q2 2024.
  • Stonepine Capital Management opened 11 new positions and closed 6 in Q2 2024.
  • Stonepine Capital Management's portfolio value fell 13% quarter-over-quarter to $110M.

Based on Stonepine Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.